Veru Inc (NASDAQ:VERU) is set to release its Q3 2025 earnings on Aug 12, 2025. The consensus estimate for Q3 2025 revenue is $0.65 million, and the earnings are expected to come in at -$0.05 per share ...

Veru and its shareholders had high hopes for sabizabulin, an orally administered COVID treatment. These hopes were diminished greatly on Wednesday, when a Food and Drug Administration (FDA) advisory ...

Veru Inc. has pivoted to focus on preventing lean mass reduction in patients using GLP-1 agonists, leveraging its lead asset, enobosarm. A Phase 2b trial showed that a 3mg dose of Enobosarm reduces ...

Veru's (VERU) share price went into meltdown last week, sinking by >35% to a price of $6.6 by market close on Nov. 11. Traded share price at the time of writing is $6.3 - its lowest since early April.

Veru agreed to conduct a clinical study of one of its treatments in combination with Novo Nordisk's Wegovy weight loss drug. Under the terms of a supply agreement with Novo, Veru will conduct and ...

Veru (VERU) stock has not been easy to own. The little biotech has spent years persuading investors that its experimental obesity technique can matter in a market dominated by giants. That's a tough ...

MIAMI - Veru Inc. (NASDAQ:VERU), a clinical-stage biopharmaceutical company whose stock has declined over 22% in the past week according to InvestingPro data, has selected a novel modified release ...

CEO Mitchell Steiner highlighted Veru's transition to a pure-play late clinical stage biopharmaceutical company focused on cardiometabolic and inflammatory diseases, following the divestiture of the ...

Insiders were net buyers of Veru Inc.'s (NASDAQ:VERU ) stock during the past year. That is, insiders bought more stock than they sold. While we would never suggest that investors should base their ...